FMP

FMP

Enter

SUPN - Supernus Pharma...

photo-url-https://images.financialmodelingprep.com/symbol/SUPN.png

Supernus Pharmaceuticals, Inc.

SUPN

NASDAQ

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

36.92 USD

0.49 (1.33%)

Historical Prices

From:

To:

page loading card

About

ceo

Mr. Jack A. Khattar M.B.A.

sector

Healthcare

industry

Drug Manufacturers - Specialty & Generic

exchange

NASDAQ

Description

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hy...

CIK

0001356576

ISIN

US8684591089

CUSIP

868459108

Address

9715 Key West Avenue

Phone

301 838 2500

Country

US

Employee

652

IPO Date

May 1, 2012

Financial Statement

-30M030M60M90M120M150M180M2023 Q32023 Q42024 Q12024 Q22024 Q3RevenueNet Income

Earnings

-0.300.30.60.91.22023 Q12023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q4EPS Consensus

SUPN Financial Summary

CIK

0001356576

Exchange

NASDAQ

Industry

Drug Manufacturers -...

Sector

Healthcare

CUSIP

868459108

ISIN

US8684591089

Country

US

Price

36.92

Beta

0.87

Volume Avg.

347.81k

Market Cap

2.04B

Shares

-

52-Week

25.53-39.37

DCF

88.97

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

34.5

P/B

-

Website

https://www.supernus.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest SUPN News

Zacks Investment Research

Aug 9, 2024

Does Supernus (SUPN) Have the Potential to Rally 28.65% as W...

The consensus price target hints at a 28.7% upside potential for Supernus (SUPN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Seeking Alpha

Aug 6, 2024

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Stacy Ku - TD Cowen Annabel Samimy - Stifel Operator Good afternoon, and welcome to the Supernus Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. A...

Zacks Investment Research

Aug 6, 2024

Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have t...

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research

Aug 6, 2024

Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.37 per share. This compares to loss of $0.02 per share a year ago.

InvestorPlace

Jul 19, 2024

If You Can Only Buy One Biotech Stock in July, It Better Be ...

When I think of biotech stocks, I imagine volatile share prices and plenty of red ink. I also think of big-time shareholder returns for the industry's winners.

GlobeNewsWire

May 30, 2024

Supernus Pharmaceuticals to Participate in the Jefferies Glo...

ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:30 p.m. ET at the Marriott Marquis Hotel in New York City.

Zacks Investment Research

May 8, 2024

Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look a...

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research

May 7, 2024

Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall St...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Supernus (SUPN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep